SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech - Technical Analysis

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (438)6/20/2002 1:42:49 PM
From: Jibacoa  Read Replies (1) of 544
 
GNLB Had a good up-gap today after it announced that European regulators would allow the company to apply for approval of its treatment for lupus through a centralized marketing application that could allow the drug to be approved throughout the European Union.(An FDA decision on approval of Aslera is expected by the end of August).(The FDA originally rejected the S.L.E. drug in June 2001)

GNLB stock seems that it may test its May and even its January Hs.<g>

siliconinvestor.com

siliconinvestor.com

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext